Navigation Links
Biogenerics Will Save Billions, Says Hospira CEO
Date:9/6/2007

- GPhA Keynote Emphasizes Generic Industry Readiness and Questions Fiscal

and Social Responsibility of Delaying Biogenerics -

WASHINGTON, Sept. 6 /PRNewswire-FirstCall/ -- Expensive biologic medicines are arriving at a critical crossroads as decades-old patents expire, and generic companies stand ready to add biogenerics to the industry's portfolio. Now is the time to pass legislation enabling the U.S. Food and Drug Administration (FDA) to create an abbreviated regulatory pathway for safe, pure and effective biogenerics, Hospira CEO and Chairman Christopher Begley said today in a keynote address at the Generic Pharmaceutical Association's (GPhA) Annual Policy Conference.

Biologic medicines, unlike traditional pharmaceuticals, are manufactured from complex living cells. They provide some of the most effective treatment options for serious diseases like cancer and diabetes, but are very expensive. A biologic to treat colon cancer, for example, costs $100,000 a year.(1) Some biologics can cost up to $200,000 annually.(2)

"When life-saving drugs are not affordable -- regardless of their safety and efficacy -- they are irrelevant," Begley said.

Representing about 250 of the more than 10,000 drugs approved by the FDA, branded biologics claim a disproportionate share of the nation's healthcare spending: (3,4)

-- In 2006, sales of biologics rose to the $30 to $40 billion range,

accounting for about 15 percent of all U.S. drug sales. (2,5)

-- In 2006, biologics cost Medicare Part B alone more than

$5 billion.(2)

-- Corporations have testified before Congress that they can't continue

to sustain the growing contribution of biologics to their employee

healthcare costs.(6)

Taking the stage in Washington, in front of approximately 200 attendees, Begley said when the technology exists today to create effective, safe and less expensive biogenerics, the continual lack of a
'/>"/>

SOURCE Hospira, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... ... 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert considers ... drug/device combinations. The current system received a score of 0 (range -10 to +10) ... (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... March 9 Campbell Alliance, the leading management ... industry, today announced that Joe Dillon has joined ... work closely with the Business Development Practice to ... and develop comprehensive strategies related to in- and ...
... 9 Human Genome Sciences, Inc. (Nasdaq: ... sponsor a conference call to discuss the results of ... alfa-2b) in patients with genotype 1 chronic hepatitis C.(Logo: ... by senior management and will be held on Monday, ...
... Nature Materials (09 March 2009) reveals how an ... Centre for Nanotechnology (LCN) at UCL have discovered a novel ... prove to be a step toward the development of new ... rain. , Although the structure of regular ice is ...
Cached Biology Technology:Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 2Campbell Alliance Hires Joe Dillon, Expands Business Development Practice 3Human Genome Sciences to Sponsor Conference Call 2It's raining pentagons 2
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... 15, 2009 - (BRONX, NY) - The fact that they eat ... and other mammals are protected from the majority of fungal pathogens, ... University. The research, published in the Journal of ... the familiar 98.6o F or 37o C in people ...
... scientists have made a discovery that promises to deliver a ... effective in all mammals not just humans or another ... reads the biological ,barcodes, of infectious microbes such as food ... vaccine could be made to prevent a particular disease in ...
... study in the Oct. 15 issue of the Journal ... diet and exercise program may benefit obese patients with mild ... eliminate the condition. Results show improvement in typical ... of life and mood after the completion of a 16-week ...
Cached Biology News:Do 3 meals a day keep fungi away? 2Bug barcode readers hold out promise of universal vaccines 2Improved diet and exercise alone unlikely to cure obstructive sleep apnea in obese patients 2
(3-[125I]iodotyrosyl26)Galanin, porcine, 370 kBq, 10 uCi. Category: IODINE LIGANDS....
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
Immunogen: Synthetic peptide based on the sequence: SPSSGPSLTADSMWR Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: